Market Overview
Market Research Future (MRFR) presumes that Heart Failure POC & LOC Devices Market Size would be valued at more than USD 175.35 million by the end of 2027. The market size will most likely capture a CAGR of around 16.2% over the assessment period (2020 to 2027).
Major Boosters and Barriers
The Centre for Disease Control & Prevention estimates that close to 7.7 million individuals in the United States are affected by heart failure. The condition is marked by the heart’s inability to pump sufficient blood as well as oxygen that are required for supporting all the other organs in the human body. It is a serious disorder, although the heart continues to beat. But past reports show that more than half of the patients that developed heart failure die within 6 years of being diagnosed.
Heart failure has emerged as one of the most lethal health conditions in the world and affects patients that lead unhealthy lifestyle and face poor prognosis. Risk factors are hypertension, obesity and diabetes, all of which have been witnessing a surge in the global current population. Unmet medical needs are quite high, especially in emerging regions, and the demand for reduced mortality should elevate the need for more advanced POC and LOC devices in the future.
People aged over 60 years form the biggest target patient base in the global market. This age group is marked by compromised immunity levels and hence, are more susceptible to chronic ailments such as heart failure. In short, the consistently blossoming elderly patient base worldwide would have a remarkable impact on the heart failure POC and LOC devices in the next several years.
Market Segmentation
Major test types are metabolomic testing, genomic testing, and proteomic testing. The leading spot belongs to the proteomic testing segment, thanks to the heightened need for biomarker testing with the use of proteomic testing.
The top technologies covered in the report for the heart failure POC & LOC devices industry are array-based systems, microfluidics, and more. The microfluidics category has secured the biggest portion of the market, since this technology facilitates integration as well as miniaturization of majority of the functional protocols utilized in central laboratories into microfluidic biosensors or portable chips.
The top segments, with respect to end user, are specialty centers, homecare, hospitals& clinics, and more.
Regional Insight
North America successfully procures the top spot in the worldwide market, thanks to the huge burden of heart conditions like cardiovascular disorder, and more. Large-scale healthcare expenditure combined with the rise in obesity cases add to the market worth as well. Besides, the surging prominence of a poor lifestyle that includes over-consumption of alcohol, smoking, and lack of exercise has foster the vulnerability of people to heart failure. This has created a favorable scenario for the North American market for heart failure POC and LOC devices.
The second position in the heart failure POC and LOC devices market belongs to Europe, and the region can expect more growth in the next couple of years. Surging incidences of cardiovascular diseases combined with the soaring number of heavy smokers amplifies the demand for these devices too. The European industry further benefits from the mushrooming elderly patient base facing a host of heart related issues due to advancing age.
Asia Pacific could expect rapid expansion in subsequent years, thanks to the blossoming patient pool paired with the rising number of technological innovations in healthcare. The fast business growth in the region, especially in India, Singapore, Japan, and China is also the result of the surge in people’s per capita income and the surge in government initiatives to upgrade the healthcare infrastructure.
Major Firms
The major heart failure POC and LOC devices producers in the market include healrth Danaher (US), bioMérieux S.A (France), Quidel Corporation (US), Siemens Healthineers (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Abaxis, Inc. (US), JantPharmacal Corporation (US), Trinity Biotech (Ireland), Instrumentation Laboratory Company (US), Abbott (US), and more.
Latest News
November 2021
EBR Systems has managed to attain a total funding of AU$110 million in Initial Public Offering on the Australian Securities Exchange (ASX). The company’s WiSE CRT System is the first-ever and the only heart failure-based wireless endocardial left ventricle pacing system. The device offers treatment to those unable to get CRT from a conventional lead-based device or patients that are at high risk associated with an upgrade surgery.
More Details@ https://www.marketresearchfuture.com/reports/heart-failure-poc-and-loc-devices-market-10650
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
